ReviewPaediatric drugs2018
State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.
Review in Paediatric drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial to Determine the Efficacy of Ketamine as an Adjunct for Pain Management in Patients With Sickle Cell Crisis
Fluid Management in Sickle Cell Disease Vaso-occlusive Crisis: Restrictive Versus Liberal Strategies: A Randomized Controlled Trial (FLASC Trial)
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Pain Control for Sickle Cell Crisis, a Novel Approach? A Retrospective Study.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Evaluation of non-opioid therapies for pain management of sickle cell disease: a literature-based review.Annals of hematology · 2026Review
- Analgesic Utilization Pattern and Cost of Managing Children with Sickle Cell Diseases: a Retrospective Single-site Audit.Journal of racial and ethnic health disparities · 2026Article
- Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Beyond the traditional oncology patient: the role of palliative care in patients with sickle cell disease receiving stem cell transplantation or gene therapy.Frontiers in oncology · 2025Article
- Exercise as a therapy for sickle cell-associated musculoskeletal pain among children: Healthcare professionals' perspectives.PloS one · 2025Article
- Advancing life: innovative approaches to enhance survival in sickle cell anemia patients.Annals of medicine and surgery (2012) · 2024Review
- Article
- A comparison of the mixed and sequential use of acetaminophen and dexketoprofen in painful vaso-occlusive crises.European journal of clinical pharmacology · 2024Article
- Predicting Pain in People With Sickle Cell Disease in the Day Hospital Using the Commercial Wearable Apple Watch: Feasibility Study.JMIR formative research · 2023Article
- Treatment Options That Reduce the Duration of Sickle Cell Vaso-Occlusive Crises: A Systematic Review.Cureus · 2022Review
- Isolation and Characterisation of Quercitrin as a Potent Anti-Sickle Cell Anaemia Agent fromJournal of clinical medicine · 2022Article
- Prevalence of neuropathic pain in adolescents with sickle cell disease: A single-center experience.Pediatric blood & cancer · 2022Article
- Moving Toward a Multimodal Analgesic Regimen for Acute Sickle Cell Pain with Non-Opioid Analgesic Adjuncts: A Narrative Review.Journal of pain research · 2022Review
- Current and novel therapies for the prevention of vaso-occlusive crisis in sickle cell disease.Therapeutic advances in hematology · 2020Review
- Updating the Brazilian clinical practice guidelines for sickle cell disease: Recommendations and development process.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute vaso-occlusive crisis (VOC) is a hallmark of sickle cell disease (SCD). Multiple complex pathophysiological processes can result in pain during a VOC. Despite significant improvements in the understanding and management of SCD, little progress has been made in the management of pain in SCD, although new treatments are being explored. Opioids and non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay of treatment of VOC pain, but new classes of drugs are being tested to prevent and treat acute pain. Advancements in the understanding of the pathophysiology of SCD and pain and the pharmacogenomics of opioids have yet to be effectively utilized in the management of VOC. Opioid tolerance and opioid-induced hyperalgesia are significant problems associated with the long-term use of opioids, and better strategies for chronic pain therapy are needed. This report reviews the mechanisms of pain associated with acute VOC, describes the current management of VOC, and describes some of the new therapies under evaluation for the management of acute VOC in SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.